Topics

Alpha LIduronidase Pipeline Review, H2 2019 [Published by Global Markets Direct] Prices from USD $2975

05:34 EST 1 Feb 2020 | BioPortfolio Reports

Alpha LIduronidase Pipeline Review, H2 2019


Summary


Alpha LIduronidase IDUA or EC 3.2.1.76 pipeline Target constitutes close to 12 molecules. Out of which approximately 11 molecules are developed by companies and remaining by the universities/institutes. The latest report Alpha LIduronidase Pipeline Review, H2 2019, outlays comprehensive information on the Alpha LIduronidase IDUA or EC 3.2.1.76 targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action MoA, route of administration RoA and molecule type.


Alpha LIduronidase IDUA or EC 3.2.1.76 Alpha Liduronidase is an enzyme encoded by IDUA gene. It hydrolyzes the terminal alphaLiduronic acid residues of two glycosaminoglycans, dermatan sulfate and heparan sulfate. Mutations in this gene that result in enzymatic deficiency lead to the autosomal recessive disease mucopolysaccharidosis type I MPS I. The molecules developed by companies in Phase II, Phase I, Preclinical and Discovery stages are 3, 1, 6 and 1 respectively. Similarly, the universities portfolio in Discovery stages comprises 1 molecules, respectively. Report covers products from therapy areas Genetic Disorders which include indications Mucopolysaccharidosis I MPS I Hurler Syndrome .


Furthermore, this report also reviews key players involved in Alpha LIduronidase IDUA or EC 3.2.1.76 targeted therapeutics development with respective active and dormant or discontinued projects. Driven by data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industryspecific third party sources.


Scope


The report provides a snapshot of the global therapeutic landscape for Alpha LIduronidase IDUA or EC 3.2.1.76

The report reviews Alpha LIduronidase IDUA or EC 3.2.1.76 targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industryspecific sources

The report covers pipeline products based on various stages of development ranging from preregistration till discovery and undisclosed stages

The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, RD brief, licensing and collaboration details other developmental activities

The report reviews key players involved in Alpha LIduronidase IDUA or EC 3.2.1.76 targeted therapeutics and enlists all their major and minor projects

The report assesses Alpha LIduronidase IDUA or EC 3.2.1.76 targeted therapeutics based on mechanism of action MoA, route of administration RoA and molecule type

The report summarizes all the dormant and discontinued pipeline projects

The report reviews latest news and deals related to Alpha LIduronidase IDUA or EC 3.2.1.76 targeted therapeutics


Reasons to buy


Gain strategically significant competitor information, analysis, and insights to formulate effective RD strategies

Identify emerging players with potentially strong product portfolio and create effective counterstrategies to gain competitive advantage

Identify and understand the targeted therapy areas and indications for Alpha LIduronidase IDUA or EC 3.2.1.76

Identify the use of drugs for target identification and drug repurposing

Identify potential new clients or partners in the target demographic

Develop strategic initiatives by understanding the focus areas of leading companies

Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics

Devise corrective measures for pipeline projects by understanding Alpha LIduronidase IDUA or EC 3.2.1.76 development landscape

Develop and design inlicensing and outlicensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Original Article: Alpha LIduronidase Pipeline Review, H2 2019 [Published by Global Markets Direct] Prices from USD $2975

NEXT ARTICLE

More From BioPortfolio on "Alpha LIduronidase Pipeline Review, H2 2019 [Published by Global Markets Direct] Prices from USD $2975"

Quick Search

Relevant Topics

Enzymes
Enzymes are proteins that catalyze (i.e., increase the rates of) chemical reactions. In enzymatic reactions, the molecules at the beginning of the process, called substrates, are converted into different molecules, called products. Almost all chemical re...

Bioinformatics
Bioinformatics is the application of computer software and hardware to the management of biological data to create useful information. Computers are used to gather, store, analyze and integrate biological and genetic information which can then be applied...

Clincial Trials
In a clinical trial or interventional study, participants receive specific interventions according to the research plan or protocol created by the investigators. These interventions may be medical products, such as drugs or devices; procedures; or change...